NCT05789173View on ClinicalTrials.gov

Interaction of CYP2B6 Genotype and Efavirenz with Methadone and Tizanidine PK

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 6, 2023

Primary Completion Date

April 15, 2026

Study Completion Date

April 15, 2026

Conditions
Drug-Drug Interaction
Interventions
DRUG

Methadone and Tizanidine

Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth at baseline (control)

DRUG

Efavirenz, Methadone and Tizanidine

Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth after pretreatment with efavirenz (600 mg PO for 16 days)

Trial Locations (1)

46202

RECRUITING

Indiana University School of Medicine, Indianapolis

All Listed Sponsors
collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

lead

Indiana University

OTHER